bioRxiv · 10.1101/2025.11.20.689585
The Human-In-the-Loop Drug Design Framework with Equivariant Rectified Flow
Abstract
Advancements in AI-based drug design often face obstacles due to incomplete datasets, hindering progress to clinical trials. Human experts bring invaluable expertise and nuanced contextual understanding to drug design. There are two main difficulties in integrating human knowledge into the drug development process. First, human annotations are costly, and traditional machine learning algorithms require a large number of samples to be effective. Second, human experts are unable to accurately describe their expertise using natural language, nor can they precisely specify what kind of molecule is needed before seeing the generated molecules. To address these problems, we propose a new platform, called HIL-DD, for experts to infuse their experience by selecting molecules generated by AI that meet their criteria, or discarding those that do not. The core generative technology utilizes an Equivariant Rectified Flow Model (ERFM), which offers faster generation speeds than conventional diffusion models, enabling efficient human-AI collaboration. More importantly, we provide a user-friendly interface to ensure smooth and effective collaboration between human experts and AI systems. Rigorous experiments demonstrate that our system can produce 3D molecules that align with expert expectations in minimal interactive sessions. These generated molecules maintain drug-like qualities comparable to those created by current state-of-the-art models.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Zhao, Y., Huang, Y., Peng, X., Lin, H., Xu, Q., Shi, Y., Liu, X., Wang, Y., Liu, Q., Peng, J., Ma, J.. 2025-11-21. The Human-In-the-Loop Drug Design Framework with Equivariant Rectified Flow. https://doi.org/10.1101/2025.11.20.689585
Cite the original work for its findings. Save a collection to share your selection of sources.